The Journal of Clinical and Aesthetic Dermatology

04/17/2026

In this month's Resident's Corner Arvin Jadoo, MD, FAAD, discusses Selecting and Transitioning EMR Systems in Dermatology: Key Considerations and Opportunities for Residents. Learn more: https://ow.ly/X0Rh50YFfwP

04/16/2026

An Analysis of Thyrotropin Levels in Patients With Nonscarring Alopecia: A Single-Center Retrospective Comparative Study

This study aims to compare thyrotropin (TSH) levels across nonscarring alopecia (NSA) subtypes—alopecia areata (AA), telogen effluvium (TE), and androgenetic alopecia (AGA)—in a primary analysis of all patients, a secondary analysis of euthyroid patients stratified into low-normal (0.5–2.5 mIU/L) and high-normal (2.5–4.5 mIU/L) categories, and a tertiary analysis of patients with thyroid dysfunction. Learn more: https://ow.ly/qz7n50YFGEL

04/15/2026

Low-Dose Isotretinoin: An Option for the Treatment of Scalp and Facial Rosacea.

This study suggests that low-dose, short-duration isotretinoin is a viable and effective systemic treatment option for extrafacial rosacea and may fill an important gap in the management of refractory scalp disease. Learn more: https://jcadonline.com/low-dose-isotretinoin-an-option-for-the-treatment-of-rosacea/

04/13/2026

The Treatment of Perioral (Periorificial) Dermatitis With Topical Roflumilast 0.3% Cream: An Illustrative Case Study With Rapid Onset and Prolonged Remission.

This article presents the case of a 30-year-old female patient who presented with periorificial dermatitis, which cleared in 5 days with once daily roflumilast cream, 0.3%, without adverse events, tolerability concerns, or recurrence 11 months after treatment initiation. Learn more: https://ow.ly/yWOe50YFEUL

04/11/2026

Severe Nail Psoriasis and Early Psoriatic Arthritis: Illustrative Cases Confirming That Severity of Disease Is Not Solely Dependent on the Extent of Body Surface Area.

This article describes the use of bimekizumab, a dual interleukin (IL) 17A and IL-17F inhibitor, for the rapid resolution of severe psoriasis in 2 patients with extensively dystrophic fingernail psoriasis and concomitant PsA, both causing marked interference with daily physical functioning and significant psychosocial impairment. Both patients rapidly achieved marked improvement of all signs and symptoms of severe psoriasis involving all affected fingernails and joints, within at least 1 to 3 months. Learn more: https://ow.ly/H4ak50YFEsZ

04/10/2026

Optimizing Surgical Tray Setup and Instrument Selection in Dermatologic Surgery: A well-organized surgical tray and deliberate instrument selection are essential components of high-quality dermatologic surgery. Proper setup enhances workflow efficiency, minimizes errors, and supports patient safety. Moreover, growing attention to cost and sustainability highlights the importance of reducing instrument waste without compromising the quality of care. This article reviews best practices for tray preparation, discusses historical and modern perspectives on instrument selection, and provides practical recommendations for improving efficiency in dermatologic surgery. Learn more: https://ow.ly/LHGt50YFE8p

04/09/2026

Plant Exosome Injection: A New Boost for Postlaser Vascular Repair. This study aims to investigate how 2 distinct PDNV formulations modulate CD31 expression and CD31+ microvascular density in standardized blue diode laser wounds created in rabbit tongue tissue. Learn more: https://ow.ly/loZx50YFCC0

04/08/2026

The April 2026 issue of JCAD is now available!
Access the digital edition here: https://ow.ly/RvcS50YFCgv

04/03/2026

James Del Rosso, DO, and David Cotter, MD, PhD, discuss the clinical safety and efficacy of nemolizumab for patients with atopic dermatitis (AD). They highlighted a case of an 11-year-old female patient with severe AD who switched from dupilumab (Dupixent) to nemolizumab (Nemluvio). The patient achieved rapid itch reduction and resolution of conjunctivitis and facial erythema. In another case, a 22-year-old female patient with long-standing AD and joint pain switched to nemolizumab, experiencing significant improvement in itch and facial erythema within 2 months. The discussion emphasizes the importance of individualized treatment and the evolving therapeutic landscape for AD. Learn more: https://jcadonline.com/podcast/james-del-rosso-do-and-david-cotter-md-phd-clinical-management-of-conjunctivitis-erythema-and-arthralgia-in-ad/

03/31/2026

Lawrence Eichenfield, MD, discusses findings from the pediatric TRuE-AD3 trial evaluating topical ruxolitinib. Learn more:

Peer-reviewed, evidence-based insights for dermatologists on the latest techniques and advanced practice management in clinical & cosmetic dermatology.

03/27/2026

Come visit the JCAD team at our AAD booth 2040 today and tomorrow!

03/27/2026

Cutaneous lichenoid drug eruptions (LDE) are a group of relatively uncommon adverse drug reactions characterized by widespread erythematous to violaceous scaly papules that can be difficult to differentiate from idiopathic lichen planus. Their increasing prevalence with the use of biologics, tyrosine kinase inhibitors, and immune checkpoint inhibitors has become of particular interest in dermatology. Learn more: https://ow.ly/gPwp50YqrOG